在SIINFEKL抗原中的β-氨基酸替代改变了免疫学识别
Ichwaku Rastogi1, John A Mannone2, Ruslan Gibadullin2
1Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Cancer biology & therapy
|April 9, 2025
概括
使用β-氨基酸的改性类疫苗显示出稳定性的承诺,但未能诱导交叉反应性T细胞或抗瘤效应,限制了它们在癌症疫苗开发中的使用.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗开发 疫苗开发
- 类化学 类化学
背景情况:
- 类疫苗提供有针对性的免疫反应,但由于酶蛋白解导致不稳定.
- 用β-氨基酸取代α-氨基酸可以通过损害蛋白质分解来增强的稳定性.
- 之前的研究探讨了包括SIINFEKL在内的卵胺 (OVA) 类类似物中的α-β氨基酸替代.
研究的目的:
- 重新检查 alpha/beta SIINFEKL 类型的稳定性和T细胞激活.
- 评估这些改性的体内免疫反应和抗瘤疗效.
- 确定脊柱改性的作为抗瘤疫苗的潜力.
主要方法:
- 在小鼠血清中测试了alpha/beta SIINFEKL抗原的蛋白质分解易感性.
- 评估了抗原在体外激活OVA特异性CD8T细胞的能力.
- 在原始和瘤携带小鼠体内评估免疫性和抗瘤作用.
主要成果:
- 阿尔法/β抗原表现出与血清中的原生抗原相似的蛋白质分解敏感性.
- 所有的α/β抗原在体外成功激活了抗原特异性CD8T细胞.
- 在体内免疫接种alpha/beta类似物并没有诱导对原生抗原或抗瘤效应的交叉反应.
结论:
- 虽然SIINFEKL的α/β类比可以引起T细胞反应,但它们在体内与原生抗原没有交叉反应.
- 脊柱改性,尽管稳定性得到了改善,但对于开发有效的抗瘤疫苗来说并不有希望.
更多相关视频
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
14.0K
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.4K
相关概念视频
00:42Cross-reactivity
30.9K
Overview
30.9K
02:28Leaky Scanning
5.0K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.0K
01:24B Cell Activation and Differentiation
1.3K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.3K